Title	Tumor response
Number of Patients Screened	19
Number of Patients Enrolled	10
Number of Patients Evaluable for Toxicity	10
Number of Patients Evaluated for Efficacy	8
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 0 (0%)
Response Assessment PR	n = 1 (10%)
Response Assessment SD	n = 3 (30%)
Response Assessment PD	n = 4 (40%)
Response Assessment OTHER	n = 2 (20%)
Median Duration of Treatment	8.4 weeks
Outcome Notes	For Response Assessment, "OTHER" denotes not evaluable (efficacy could not be assessed in two patients because they had no postbaseline tumor assessment).